Uracil derivatives as AXL and c-MET kinase inhibitors
US9120778B2 · kind B2 · utility
4Cited by
1References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 8, 2015 |
| Grant date | Sep 1, 2015 |
| Priority date | — |
| Expiry date | Apr 8, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D491/056
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present application provides compounds of Formula Ior salt forms thereof, wherein Ra, Rb, Rc, Rd, D, W, R1a, R1b, R1c, Y, R3, X, E and G are as defined herein, compositions, methods of treatment and uses thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.